May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
The Effects of Intraocular Triamcinolone on Persistent Diabetic Macular Edema as Measured by Optical Coherence Tomography (OCT)
Author Affiliations & Notes
  • J.D. McCluskey
    Ophthalmology, University of Mississippi, Jackson, MS
  • H. Wafapoor
    Ophthalmology, University of Mississippi, Jackson, MS
    VA Medical Center, Jackson, MS
  • C.J. Chen
    Ophthalmology, University of Mississippi, Jackson, MS
  • L.L. Chen
    Ophthalmology, University of Mississippi, Jackson, MS
  • M.L. Palmer
    Ophthalmology, University of Mississippi, Jackson, MS
    VA Medical Center, Jackson, MS
  • W. May
    Ophthalmology, University of Mississippi, Jackson, MS
  • Footnotes
    Commercial Relationships  J.D. McCluskey, None; H. Wafapoor, None; C.J. Chen, None; L.L. Chen, None; M.L. Palmer, None; W. May, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 2974. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J.D. McCluskey, H. Wafapoor, C.J. Chen, L.L. Chen, M.L. Palmer, W. May; The Effects of Intraocular Triamcinolone on Persistent Diabetic Macular Edema as Measured by Optical Coherence Tomography (OCT) . Invest. Ophthalmol. Vis. Sci. 2004;45(13):2974.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:To examine the effects of Intraocular Triamcinolone (ITC) on macular thickness as measured by OCT in Persistent Diabetic Macular Edema (PDME). Methods: A retrospective chart review of patients that had PDME following grid or focal laser was performed from November 2002 until January 2004. All patients that were treated with 4 mg ITC injection were included in the study. Prior to ITC a complete eye exam including fluorescein angiography and OCT was performed. This exam was repeated at 1, 3, and 6 months. The following demographic information was also collected on each patient: age, sex, race, body mass index, blood pressure, HgbA1C, tobacco use, lipid profile, statin medications, and insulin use. Results: A total of 21 patients (21 eyes) were included in the study. Age ranged from 58–80 years old. Race included 14 caucasian patients and 7 African American patients. Prior to ITC injection, the foveal thickness (FT) was 439 + 161 µ , inner macular thickness (IMT) ranged from 373 + 118 µ to 416 + 69 µ, outer macular thickness (OMT) ranged from 281 + 51µ to 321 + 63µ . Visual acuity before ITC injection ranged from 20/25 to count finger. The FT at 1, 3, 6 months following ITC injection was 241 + 50 µ, 262 + 92 µ, and 346 + 118 µ. There was a 40–45% reduction in FT at 1 and 3 months, the reduction was 20% at 6 months. This reduction pattern was also seen for IMT and OMT. The visual acuity of 5 patients improved 2 or more Snellen lines. Vision remained stable in 15 patients and one patient had a decrease in vision. The most common complication was increased intraocular pressure. Conclusions: ITC may be considered as a treatment for PDME. A significant decrease in macular thickness by OCT was measured at 1 and 3 months follow up. However, the effectiveness of intraocular triamcinolone may decrease at six months. Visual acuity improved or remained stable in 20 out of 21 patients.

Keywords: diabetic retinopathy • drug toxicity/drug effects • visual acuity 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×